Publication: Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations
dc.contributor.author | Ariza, Javier | |
dc.contributor.author | Bosilkovski, Mile | |
dc.contributor.author | Cascio, Antonio | |
dc.contributor.author | Colmenero, Juan D. | |
dc.contributor.author | Corbel, Michael J. | |
dc.contributor.author | Falagas, Matthew E. | |
dc.contributor.author | Memish, Ziad A. | |
dc.contributor.author | Roushan, Mohammad Reza Hasanjani | |
dc.contributor.author | Rubinstein, Ethan | |
dc.contributor.author | Sipsas, Nikolaos V. | |
dc.contributor.author | Solera, Javier | |
dc.contributor.author | Young, Edward J. | |
dc.contributor.author | Pappas, Georgios | |
dc.contributor.authoraffiliation | [Ariza, J] Servicio de Enfermedades Infecciosas, Hospital de Bellvitge, Universidad de Barcelona, Barcelona, Spain. [Bosilkovski, M] Clinic for Infectious Diseases and Febrile Conditions, Clinical Center, Skopje, Former YugoslavRepublic of Macedonia. [Cascio, A] Scuola di Specializzazione in Malattie Infettive, Dipartimento di Patologia Umana, Universitadi Messina, Messina, Italy. [Colmenero, JD] Infectious Diseases Service, Carlos Haya University Hospital, Malaga, Spain. [Corbel, MJ] Division of Bacteriology, National Institute for Biological Standards and Control, Hertfordshire, United Kingdom. [Falagas, ME] Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece. [Falagas, ME] Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, United States of America. [Memish, ZA] Department of Infection Prevention and Control, King Fahad National Guard Hospital, Riyadh, Saudi Arabia. [Roushan, MRH] Department of Infectious Diseases, Yahyanejad Hospital, Babol Medical University, Babol, Iran. [Rubinstein, E] Section of Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada. [Sipsas, NV] Pathophysiology Department, Laikon General Hospital, University of Athens, Athens,Greece. [Sipsas, NV] Medical School, National and Kapodistrian University of Athens, Athens, Greece. [Solera, J] Servicio de Medicina Interna, Hospital General Universitario, Albacete, Spain. [Young, EJ] Medical Services,Veterans Affairs Medical Center, Houston,Texas,United States of America. [Pappas, G] Institute of Continuing Medical Education of Ioannina, Ioannina, Greece. [Pappas, G] Working Group on Zoonoses, International Society of Chemotherapy, London, United Kingdom. | es |
dc.date.accessioned | 2012-11-28T09:29:47Z | |
dc.date.available | 2012-11-28T09:29:47Z | |
dc.date.issued | 2007-12 | |
dc.description | Policy Forum. Competing interests: ER has received research grants from Daiichi, Bayer, and Theravance and has served as a consultant to Pfizer, Theravance, Bayer, Wyeth, Rosetta, and BiondVax. | es |
dc.description.abstract | Summary Points Brucellosis remains the commonest anthropozoonosis worldwide, and its treatment remains complex, requiring protracted administration of more than one antibiotic. In November 2006, a consensus meeting aimed at reaching a common specialist statement on the treatment of brucellosis was held in Ioannina, Greece under the auspices of the International Society of Chemotherapy and the Institute of Continuing Medical Education of Ioannina. The author panel suggests that the optimal treatment of uncomplicated brucellosis should be based on a six-week regimen of doxycycline combined either with streptomycin for 2–3 weeks, or rifampicin for six weeks. Gentamicin may be considered an acceptable alternative to streptomycin, while all other regimens/combinations should be considered second-line. The development of a common global therapeutic language for human brucellosis, and future, properly conducted clinical trials would definitely solve controversies regarding the disease. | es |
dc.description.version | Yes | es |
dc.identifier.citation | Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al. Perspectives for the treatment of brucellosis in the 21st century: The ioannina recommendations. Plos Med. 2007 Dec;4(12):1872-8 | es |
dc.identifier.doi | 10.1371/journal.pmed.0040317 | |
dc.identifier.essn | 1549-1676 | |
dc.identifier.issn | 1549-1277 | |
dc.identifier.other | WOS000251874600008 | |
dc.identifier.pmc | PMC2222927 | |
dc.identifier.pmid | 18162038 | |
dc.identifier.uri | http://hdl.handle.net/10668/662 | |
dc.journal.title | PLoS medicine | |
dc.language.iso | en | |
dc.publisher | Public Library of Science | es |
dc.relation.publisherversion | http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0040317 | es |
dc.rights.accessRights | open access | |
dc.subject | Iraqi patients | es |
dc.subject | Cotrimoxazole | es |
dc.subject | Efficacy | es |
dc.subject | Metaanalysis | es |
dc.subject | Animales | es |
dc.subject | Antibacterianos | es |
dc.subject | Investigación Biomédica | es |
dc.subject | Brucelosis | es |
dc.subject | Países en Desarrollo | es |
dc.subject | Doxiciclina | es |
dc.subject | Combinación de Medicamentos | es |
dc.subject | Resistencia a Medicamentos | es |
dc.subject | Quimioterapia | es |
dc.subject | Fluoroquinolonas | es |
dc.subject | Gentamicinas | es |
dc.subject | Adhesión a Directriz | es |
dc.subject | Historia del Siglo XXI | es |
dc.subject | Humanos | es |
dc.subject | Recurrencia | es |
dc.subject | Estreptomicina | es |
dc.subject | Terminología como Asunto | es |
dc.subject | Resultado del Tratamiento | es |
dc.subject | Combinación Trimetoprim-Sulfametoxazol | es |
dc.subject | Salud Mundial | es |
dc.subject | Organización Mundial de la Salud | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents | es |
dc.subject.mesh | Medical Subject Headings::Disciplines and Occupations::Natural Science Disciplines::Science::Research::Biomedical Research | es |
dc.subject.mesh | Medical Subject Headings::Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Brucellosis | es |
dc.subject.mesh | Medical Subject Headings::Disciplines and Occupations::Social Sciences::Internationality::International Cooperation::Developing Countries | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthacenes::Tetracyclines::Doxycycline | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations | es |
dc.subject.mesh | Medical Subject Headings::Phenomena and Processes::Microbiological Phenomena::Drug Resistance, Microbial | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Quinolines::Quinolones::Fluoroquinolones | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Gentamicins | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Gentamicins | es |
dc.subject.mesh | Medical Subject Headings::Humanities::Humanities::History::History, Modern 1601-::History, 21st Century | es |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans | es |
dc.subject.mesh | Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds with 4 or More Rings::Rifamycins::Rifampin | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Streptomycin | es |
dc.subject.mesh | Medical Subject Headings::Information Science::Information Science::Communication::Language::Linguistics::Terminology as Topic | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Trimethoprim::Trimethoprim-Sulfamethoxazole Combination | es |
dc.subject.mesh | Medical Subject Headings::Health Care::Population Characteristics::Health::World Health | es |
dc.subject.mesh | Medical Subject Headings::Health Care::Health Care Economics and Organizations::Organizations::International Agencies::United Nations::World Health Organization | es |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals | es |
dc.title | Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations | es |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Ariza_PerspectivesForTheTreatment.pdf
- Size:
- 334.58 KB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo publicado